Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Hedge Funds Think About Avon Products, Inc. (AVP)

Page 1 of 2

To the average investor, there are many metrics shareholders can use to track Mr. Market. A couple of the best are hedge fund and insider trading movement. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the best hedge fund managers can beat their index-focused peers by a solid amount (see just how much).

Just as crucial, optimistic insider trading sentiment is another way to look at the financial markets. There are lots of reasons for a bullish insider to sell shares of his or her company, but only one, very clear reason why they would buy. Plenty of academic studies have demonstrated the useful potential of this tactic if shareholders know where to look (learn more here).

Keeping this in mind, it’s important to discuss the latest info surrounding Avon Products, Inc. (NYSE:AVP).

Avon Products, Inc. (NYSE:AVP)

How are hedge funds trading Avon Products, Inc. (NYSE:AVP)?

At the end of the second quarter, a total of 28 of the hedge funds we track held long positions in this stock, a change of 12% from the previous quarter. With the smart money’s capital changing hands, there exists an “upper tier” of key hedge fund managers who were increasing their stakes meaningfully.

According to our 13F database, Yacktman Asset Management, managed by Donald Yacktman, holds the most valuable position in Avon Products, Inc. (NYSE:AVP). Yacktman Asset Management has a $398.4 million position in the stock, comprising 1.9% of its 13F portfolio. Sitting at the No. 2 spot is Columbus Circle Investors, managed by Donald Chiboucis, which held a $84.7 million position; the fund has 0.7% of its 13F portfolio invested in the stock. Remaining hedgies that hold long positions include Phill Gross and Robert Atchinson’s Adage Capital Management, Jacob Gottlieb’s Visium Asset Management and D. E. Shaw’s D E Shaw.

With a general bullishness amongst the titans, certain money managers were leading the bulls’ herd. Yacktman Asset Management, managed by Donald Yacktman, assembled the biggest position in Avon Products, Inc. (NYSE:AVP). Yacktman Asset Management had 398.4 million invested in the company at the end of the quarter. Donald Chiboucis’s Columbus Circle Investors also made a $84.7 million investment in the stock during the quarter. The other funds with brand new AVP positions are Phill Gross and Robert Atchinson’s Adage Capital Management, Jacob Gottlieb’s Visium Asset Management, and D. E. Shaw’s D E Shaw.

What do corporate executives and insiders think about Avon Products, Inc. (NYSE:AVP)?

Insider buying made by high-level executives is most useful when the company in question has experienced transactions within the past six months. Over the last 180-day time period, Avon Products, Inc. (NYSE:AVP) has seen 3 unique insiders purchasing, and 2 insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to Avon Products, Inc. (NYSE:AVP). These stocks are Colgate-Palmolive Company (NYSE:CL), Kimberly Clark Corp (NYSE:KMB), Nu Skin Enterprises, Inc. (NYSE:NUS), Estee Lauder Companies Inc (NYSE:EL), and Energizer Holdings, Inc. (NYSE:ENR). This group of stocks are the members of the personal products industry and their market caps resemble AVP’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!